Pharmacoeconomic research of medicines used for allergic rhinitis in children
No Thumbnail Available
Date
2024-09
Journal Title
Journal ISSN
Volume Title
Publisher
Open Science Publishers LLP
Abstract
Allergic rhinitis (AR) is a common global disease, affecting approximately 2%–25% of children and 1%–40% of adults. Recent studies have shown an increasing prevalence, especially in low-income countries. Although not fatal, AR significantly impairs patients’ quality of life and is linked to bronchial asthma (BA) development. This research aimed to study the regional distribution of AR in children, analyze various medicine preparations used for treatment, and identify effective and affordable options through pharmaco-economic methods. Data from the Ministry of Healthcare of the Republic of Uzbekistan, Hospital No. 2 of the Tashkent Medical Academy, and wholesale medicine costs were analyzed. The study demonstrated the effectiveness and cost efficiency of budesonide medicines for treating AR in children with BA, resulting in significant cost savings during the first treatment session.
Description
Keywords
Budesonide, mebhydrolin, chloropyramine, budesonide mometazone furoate, medicines substances.
Citation
Suyunov N, Umurzakhova G, Blatov R, Yegizbayeva S, Abdullaeva M, Zhakipbekov K. Pharmacoeconomic research of medicines used for allergic rhinitis in children. Journal of Applied Pharmaceutical Science. 2024 Sept; 14(9): 198-207